VIPR1 and infection: SBA and OPKA titers (Fig. 7A and B), as well as IpaB- and VirG-specific IgG levels (Fig. 7C and D), were also measured in all subjects 28 days postchallenge to determine the breadth of serological responses following infection in relation to preexisting immunity and disease outcome.